FDA Removes Black Box Warnings from Hormone Therapy: Implications for Women's Health

On November 10, 2025, the Food and Drug Administration (FDA) announced the removal of "black box" safety warnings from hormone therapy products for menopause, including both systemic and topical estrogen therapies. These warnings had been in place for over two decades, indicating potential risks such as cancer, cardiovascular disease, and cognitive decline. The decision follows a reassessment of the risks and benefits associated with hormone therapy, particularly in light of new research and expert recommendations.

The Conversation

The initial warnings stemmed from findings in the early 2000s, particularly from the Women’s Health Initiative study, which suggested that hormone therapy increased the risk of serious health issues. In response, the FDA added black box warnings to all estrogen-containing products in 2003. However, subsequent analyses have highlighted methodological flaws in the original study, leading to a reevaluation of hormone therapy's safety profile.

The Conversation

At a July 2025 FDA expert panel meeting, most specialists advocated for the removal of warnings on topical vaginal estrogen products, which had been included despite their safety. Research indicates that the risks associated with systemic hormone therapy are significantly influenced by the timing of initiation, type, and dosage. For women under 60 or within ten years of menopause, hormone therapy appears to be safer, while older women may face increased cardiovascular risks.

The Conversation

Topical estrogen, used to treat genitourinary syndrome of menopause, has shown to be particularly beneficial, improving tissue quality and urinary health. Despite its safety, many healthcare providers have been hesitant to prescribe it due to the existing warnings.

The Conversation

The removal of black box warnings is seen as a positive development for women managing menopause symptoms. It may encourage more discussions between patients and healthcare providers regarding hormone therapy options. However, some experts express concern that the FDA's announcement lacks clarity on how to communicate ongoing risks associated with hormone therapy, particularly for women who may be at higher risk due to age or pre-existing conditions.

The Conversation

Critics argue that while the removal of warnings may empower women, it also risks downplaying the potential dangers of hormone therapy. They advocate for clear, visible information on packaging that outlines who can safely use hormone therapy and who should avoid it. This perspective emphasizes the need for informed decision-making based on comprehensive risk assessments.

The Conversation

• “Safety concerns that led to the black box warnings, especially in regard to local vaginal estrogen, have turned out to be overblown.” — Genevieve Hofmann, Women’s Health Nurse Practitioner

The Conversation

• “The specific language for the new HT warnings and their placement should have been made concurrently with the decision to require manufacturers to remove the Black Box.” — Marty Makary, FDA Commissioner

Hormone Therapy Just Lost Its Black Box Warning. Now the FDA Owes Women Clarity - MedShadow Foundation

The FDA's decision to remove black box warnings from hormone therapy products marks a significant shift in the approach to menopause management. While it opens the door for more women to consider hormone therapy, ongoing discussions about the risks and benefits remain crucial. As healthcare providers adapt to these changes, clear communication and patient education will be essential to ensure safe and effective treatment options for menopausal symptoms.

The Conversation